News

POLARISqb, Developers of First Quantum Drug Discovery Platform, Announces Seed Investment of $2.1 Million

POLARISqb, the Durham based developer of the world’s first drug discovery software built for quantum computers, announces that it has received the first round of their seed raise, totalling over two million dollars. This funding will allow Polaris to grow their team, scale the platform and develop assets faster. 

POLARISqb’ seed round is led by OurCrowd, and joined by Infinity Medical.OurCrowd is a global venture investing platform empowering institutions and individuals to invest and engage in emerging companies. With $1.8 billion of committed funding, and investments in more than 280 portfolio companies and 28 venture funds. Infinity Medical focused on advanced digital health technologies, with portfolio companies on the cutting edge of health innovation, in transition from development to global sales. 

 

“OurCrowd has allowed us to reach investors in a modern and engaging manner, building relationships that will provide opportunities for continued growth and connection with stakeholders from around the globe.” said POLARISqb CEO Shahar Keinan. 

 

David Sokolic, Investment Partner at OurCrowd, explains “OurCrowd has developed a cogent investment thesis around quantum computing and has made several previous related investments in enabling hardware and software development tools. We are pleased to now add POLARISqb to our growing portfolio in this rapidly emerging field. POLARISqb’s unique approach of applying the power of quantum computing to the discovery of novel drug candidates at a fraction of the time and cost of conventional methods represents one of the first commercial examples of quantum-powered application software delivering tangible benefits surpassing what was previously achievable.”

Auransa and POLARISqb Enter Research Collaboration to find Treatments for Neglected Women’s Diseases

PALO ALTO, Calif. and DURHAM, N.C.June 04, 2021 /PRNewswire/ -- Auransa, Inc., an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women.  The logo for AI healthcare company Auransa

The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.  Auransa is an AI-driven biotech company, with a pipeline of novel compounds for various diseases. Auransa's proprietary predictive computational platform, SMarTR™ Engine, uses computational approaches to tackle disease heterogeneity to predict targets and compounds, generating insights from molecular data. POLARISqb built the first drug discovery platform using quantum computing, making the process ten times faster. POLARISqb's TachyonTM platform scans billions of molecules from a massive chemical space, finding novel molecular drugs.

"We are excited about collaborating with Polaris to undertake a neglected area in the pharmaceutical industry. As women CEOs, we've joined forces to tackle female diseases like endometriosis, polycystic ovary syndrome, triple negative breast cancer or ovarian cancer. Together, I believe that we will be able to combine our expertise in biology and chemistry to generate quality solutions for hard to tackle or neglected diseases affecting women's health." stated Pek Lum, Ph.D., CEO of Auransa.

"Quantum Computing technology is coming of age, allowing us to shorten the time to discover new drugs and scale up to multiple targets. We are thrilled to be able to combine our technology with Auransa's and tackle neglected diseases affecting women. Together, we have unique perspectives on the industry and of unmet needs the pharmaceutical industry can and should tackle, utilizing the best technology available." said Dr. Shahar Keinan, POLARISqb CEO.

Auransa

Auransa is an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet need.  They are working to redefine medicine, combining a sophisticated, proprietary and predictive computational platform with traditional pharmaceutical experience.  The company's SMarTR™ Engine has proprietary machine learning, advanced analytics and mathematics in an AI framework to generate insights from molecular data for a deep understanding of disease biology and patient subtypes. Auransa has successfully generated a broad pipeline of drug candidates addressing cancer, auto-immune, infectious and metabolic diseases advancing toward investigational new drug (IND) filings.  Learn more: www.auransa.com.

Polarisqb

POLARISqb is the first drug discovery platform built for quantum computers. The company is transforming health for people everywhere, revolutionizing drug design by accelerating lead time for preclinical drug candidates. Founded in 2020 by Shahar Keinan, CEO, and Bill Shipman, CTO, POLARISqb uses the latest cloud, quantum computing, artificial intelligence, and machine learning to operate 10,000 times faster than alternative solutions. With real-time adaptability, POLARISqb can produce up to 100 drug blueprints annually. The resulting high-quality lead molecules are taken to synthesis, testing, and licensed to pharmaceutical partners for further development within months, rather than years. Learn more: www.polarisqb.com

PolarisQB Announce Hiring of Pharmacologist Ian Reynolds

Polarisqb  is proud to add Dr. Ian Reynolds, a world renowned expert in pharmacology, as an advisor to the company. Dr. Ian Reynolds is an experienced pharmaceutical executive who has been recognized for his work in small molecule drug discovery and has helped a number of academic researchers translate into the world of biotech research and drug development.

Dr. Ian Reynolds, renowned pharmacologist, is joining PolarisQB as an advisor.

Following a PhD. from Johns Hopkins in pharmacology and a postdoctoral fellowship in the University of Chicago’s Neuropharmacology department, Dr. Reynolds has been involved in a number of successful pharmaceutical ventures, including Knopp Biosciences and Teva Pharmaceuticals before taking over as the CEO of Belgium’s Rewind Therapeutics in 2018. He has studied a wide variety of Central Nervous System (CNS) diseases over the course of his career, investigating drug targets and therapeutic treatments for diseases like ALS, Parkinson’s Disease, and Multiple Sclerosis.. 

 

Both Dr. Reynolds and Polarisqb  are excited about the continued development of the Tachyontm quantum drug discovery platform, as it holds great promise for novel drug development for many diseases that have proven difficult or impossible for researchers to reach. Strong computational models will end up enabling researchers to look at much more complex chemical interactions. As Dr. Reynolds stated, “The current in silico process for drug discovery requires that scientists simplify the characteristics they are testing for, to fall within the limits of classical computational parameters. The promise of computer aided drug design on a quantum system is that researchers could factor for a multitude of properties on a single run, allowing for a much more efficient process, better results, and shorter drug development timelines.” By utilizing quantum computing, the Tachyontm platform is able to identify the right molecule that will become a drug from a library of billion molecules in a fraction of the time that it would take for classical systems to run the same combinatorial optimizations. 

 

Polarisqb is utilizing quantum computing to reduce the timelines of computer aided drug discovery many times over. Dr. Reynolds expertise in pharmacology, and especially in CNS diseases, will drive forward the promise of quantum computing aided drug design. Dr. Reynolds predicts that “The future of protein targeting will likely be 100% in silico, but we are currently in the process of transitioning between a largely wet lab dependent operation and more powerful computing solutions like the Tachyon system that Polarisqb  is building. These systems have the potential to revolutionize the optimization process and with it the entire drug research and development industry.”

Quantum Startup POLARISqb Announces Expansion into Maritime Division

POLARISqb, a Durham based startup is a company that utilizes cutting edge computing to power computational chemistry simulations, developing quantum and near quantum software that cuts drug development timelines by more than half. However, recent events on the global stage got the company thinking about other ways that its algorithms could be used, and this week has announced the creation of the POLARISqb Maritime Division. This unique endeavor from the company intends to make waves in the business of dredging, salvage, and recovery consulting, providing services to companies around the globe. They intend to be three sheets to the wind in the expansion of their client base.

The company did not waste time in seeking out a Chief Nautical Officer, and

POLARISqb Chief Nautical Officer Shil Bippman

clearly like the cut of industry veteran Shil Bippman’s jib, who has always been known to run a tight ship. “Everyone has been aware for a long time that next to chemistry, materials science is one of the most quantum applicable fields of study at present” said Bippman, “when we did the math, both literally and figuratively, doing this kept us on the right tack.” Bippman went on to explain the ways that quantum thermodynamics and hydrodynamics could easily be simulated using the latest quantum annealing computers and algorithms very similar to the ones the company had already been developing. By changing a few variables and rerouting the power coupling using a fairly experimental capacitor from Emmett Brown Quantum called simply the “Flux,” the company was able to simulate complex interactions between multiple boats and impediments such as sediment and sludge buildup in a canal, or old timey pirates.

“Sand moves in fairly predictable ways, but when you introduce water, currents, multiple tugboats, and a line of ships 500 miles long waiting to pass, a lot of variables come into play.” Bippman explained. “It is thrilling to be able to toe the line of what is possible with vanguard of modern computing to negotiate what path for the dredger is going to get everything back hunky dory, and how multiple boats can maneuver in concert to solve multimillion dollar problems.” 

When asked about recent events in the Suez canal, and whether or not their software had been used to help free the marooned ship that was blocking the important trading route, Bippman was taken aback, stating, “Oh I do not know much about that situation, was it a dredging and tugboat issue as well? Well I certainly would not comment on our work with any clientele that had made it explicitly clear that we were not, under any circumstances, to discuss the details of  our partnership with their organization. Certainly not. No.” If they were instrumental in solving that crisis, it is clear that someone has asked them to batten down the hatches and not rock the boat. However if it was POLARISqb that got that situation shipshape and Bristol fashion, expect them to be all hands on deck with this new venture, as they will have sailors storming the gangways to work with them.